Massive Bio, a leader in AI-driven oncology trial matching, has aligned with the White House and CMS’s health tech initiative to enhance clinical trial access. With its innovative Patient Connect app and intelligent assistant, DrArturoAI, the company is implementing CMS’s interoperability framework effectively. The Patient Connect app allows cancer patients to upload medical records, match to clinical trials, and securely communicate with coordinators. It features digital check-ins, identity verification, and Medicare connectivity, guaranteeing compliance and accessibility. DrArturoAI serves as a conversational support tool, providing educational resources and care navigation. Massive Bio champions health equity by streamlining patient journeys and expanding access to advanced treatments through collaboration with healthcare providers and organizations. Recognized for its commitment, Massive Bio adheres to FHIR standards and works under the CancerX partnership. For more details, visit www.massivebio.com.
